BAJAJ BROKING

Notification close image
No new Notification messages
card image
Vikram Solar IPO is Open!
Apply for the Vikram Solar IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Top Biotech Stocks in India by Market Capitalization

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

This section focuses on highlighting the leading biotech companies in India, ranked by their market capitalization. The Indian biotech sector is poised for significant growth, with a projected market valuation exceeding $150 billion by 2025.

Top 5 Biotech Stocks in India You Should Know

The table below presents some of the key biotechnology and medical research companies in India, ranked by their market capitalisation. It also includes details such as their latest stock price, percentage change, 52-week high and low values.

Company Name

Last Price (₹)

% Change

52-Week High (₹)

52-Week Low (₹)

Market Cap (₹ cr)

Biocon

325.65

-5.76%

404.60

260.00

39,097.54

Concord Biotech

1,646.30

-4.39%

2,658.00

1,326.90

17,222.97

Sun Pharma Adv

142.40

-5.04%

474.00

109.20

4,621.19

Windlas Biotech

969.80

-4.82%

1,197.00

494.70

2,032.63

Softrak Venture

3.00

+4.90%

4.93

1.21

135.23

Source: MoneyControl as of 4 Apr’25

Overview of Biotech Stocks

This brief table offers a snapshot of selected biotech stocks based on their market capitalisation. These companies are active in the biotechnology and medical research sector and reflect varied sizes and price movements.

Company Name

Market Cap (₹ cr)

Biocon

39,097.54

Concord Biotech

17,222.97

Sun Pharma Adv

4,621.19

Windlas Biotech

2,032.63

Softrak Venture

135.23

Source: MoneyControl

Biocon Ltd.

Biocon Ltd. is one of the leading biopharmaceutical firms in India with a focus on therapy areas of diabetes, oncology, and auto-immune diseases. It has diversified revenue streams in biosimilars, generics, and new biologics. It leverages advanced fermentation and recombinant DNA technologies in its R&D and manufacturing processes.

Company Overview Table: Biocon Ltd.

Metric

Value

Market Cap (₹ cr)

39,169.57

Last Price (₹)

326.25

52 Week High/Low (₹)

404.70 / 259.85

TTM EPS (₹)

6.70

TTM PE

48.69

P/B Ratio

1.87

ROE (%)

5.16

Net Profit (₹ cr)

1,382

Net Sales (₹ cr)

14,755

Debt to Equity Ratio

0.80

Source: MoneyControl

Highlights:

● Strong focus on biosimilars with international collaborations.

● Reasonable valuation with PE close to sector average.

● Stable promoter holding of 60.64% as of Dec 2024​.

Concord Biotech Ltd.

Concord Biotech Ltd. specializes in fermentation-based APIs with a presence in niche therapeutic areas such as immunosuppressants and oncology. The company has witnessed robust growth through capacity expansions and product launches.

Company Overview Table: Concord Biotech Ltd.

Metric

Value

Market Cap (₹ cr)

17,276.84

Last Price (₹)

1,651.45

52 Week High/Low (₹)

2,664.00 / 1,327.05

TTM EPS (₹)

31.38

TTM PE

52.63

P/B Ratio

10.86

ROE (%)

19.97

Net Profit (₹ cr)

304

Net Sales (₹ cr)

1,016

Debt to Equity Ratio

0.00

Source: MoneyControl

Highlights:

● Zero-debt company with improving ROE and ROCE.

● Successfully commissioned new injectable manufacturing facility.

● Promoter holding stands at 44.08% as of Dec 2024​.

Sun Pharma Advanced Research Company Ltd. (SPARC)

SPARC focuses solely on pharmaceutical R&D. It develops new chemical entities (NCEs) and novel drug delivery systems (NDDS). Its portfolio includes early- and late-stage assets across therapeutic areas like oncology, neurology, and inflammation.

Company Overview Table: Sun Pharma Adv.

Metric

Value

Market Cap (₹ cr)

4,699.40

Last Price (₹)

144.81

52 Week High/Low (₹)

472.80 / 109.30

Book Value Per Share (₹)

-2.45

ROE (%)

-310.83

Net Profit (₹ cr)

-388

Net Sales (₹ cr)

75

Debt to Equity Ratio

0.38

Source: MoneyControl

Highlights:

● Focus on novel R&D despite consistent net losses.

● Clinical pipeline includes investigational drug SBO-154 for solid tumors.

● Promoter holding at 65.67% as of Dec 2024​.

Windlas Biotech Ltd.

Windlas Biotech manufactures finished dosage formulations (FDFs), CDMO products, and domestic branded generics. Its client base includes many leading domestic pharma companies. The firm maintains a healthy financial profile and operational efficiency.

Company Overview Table: Windlas Biotech Ltd.

Metric

Value

Market Cap (₹ cr)

2,040.81

Last Price (₹)

973.70

52 Week High/Low (₹)

1,198.25 / 495.65

TTM EPS (₹)

29.25

TTM PE

33.29

P/B Ratio

4.33

ROE (%)

12.91

Net Profit (₹ cr)

58

Net Sales (₹ cr)

630

Debt to Equity Ratio

0.00

Source: MoneyControl

Highlights:

● Debt-free status with consistent double-digit ROE.

● Recent sales growth over 20% Y-o-Y in Q3 FY25.

● Promoter holding steady at 62.51% as of Dec 2024​.

Softrak Venture Investment Ltd.

Softrak Venture operates at the intersection of IT services and healthcare R&D. Although categorized under biotech, its operations are more aligned with enabling healthcare digitization through technology solutions.

Company Overview Table: Softrak Venture Ltd.

Metric

Value

Market Cap (₹ cr)

135.23

Last Price (₹)

3.00

52 Week High/Low (₹)

4.93 / 1.21

TTM EPS (₹)

0.07

TTM PE

42.86

P/B Ratio

0.30

ROE (%)

4.76

Net Profit (₹ cr)

2

Net Sales (₹ cr)

0

Debt to Equity Ratio

0.00

Source: MoneyControl

Highlights:

● Micro-cap firm with IT-biotech hybrid positioning.

● Registered over 100% stock appreciation YoY in April 2024.

● No promoter holding as per Dec 2024 shareholding data​.

How To Invest In Biotech Stocks?

To invest in biotech stocks effectively, it is crucial to conduct thorough research on the companies involved. This includes analyzing their financial health, product pipelines, and market positioning. Opening a demat account is essential for holding and trading shares electronically. Diversification across different sectors and focusing on established companies with robust financials can help mitigate risks. Staying updated on market trends and regulatory developments is also vital for making informed investment decisions.

Conclusion

Investing in biotech stocks offers a promising avenue for growth, driven by India's thriving biotech industry and supportive government policies. While biotech stocks come with inherent risks, the chance they'll bring high returns and resilience under economic downturns is attractive to risk-tolerant and long-term investors. To boost returns, investors should stay informed about market trends and regulatory developments. Utilizing tools like a brokerage calculator can help assess potential returns and risks more effectively.

Other Popular Stocks in India

Here are other notable companies in India's biotechnology sector that are actively contributing to innovation and growth across therapeutic and research domains:

Laurus Labs Ltd. 
 Focuses on high-volume API manufacturing and has diversified into formulation and biotech segments including recombinant protein production.

Shilpa Medicare Ltd. 
 Specializes in oncology APIs and formulations, with increasing investments in biologics and biosimilars through its dedicated biopharma division.

Syngene International Ltd. 
 Operates as a contract research and manufacturing organization (CRAM), providing integrated discovery, development, and manufacturing services to global pharma and biotech firms.

Neuland Laboratories Ltd. 
 Known for its expertise in process R&D and API production, the company is increasing its footprint in complex molecules and biotech intermediates.

Aarti Drugs Ltd. 
 While primarily focused on pharmaceuticals, the company is expanding capabilities into biotech-based products and niche therapeutic categories.

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|